Sapoven T 200 mg + 20 mg Kapsułka, miękka Польща - польська - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

sapoven t 200 mg + 20 mg kapsułka, miękka

przedsiębiorstwo produkcji farmaceutycznej hasco-lek s.a. - troxerutinum + hippocastani seminis extractum siccum normatum - kapsułka, miękka - 200 mg + 20 mg

Rutinosal C 300 mg + 20 mg + 40 mg Tabletki Польща - польська - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

rutinosal c 300 mg + 20 mg + 40 mg tabletki

laboratorium farmaceutyczne labofarm sp. z o.o. sp. k. - salicis cortex + rutosidum trihydricum + acidum ascorbicum - tabletki - 300 mg + 20 mg + 40 mg

Venescin (118 mg + 20 mg)/g Żel Польща - польська - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

venescin (118 mg + 20 mg)/g Żel

wrocławskie zakłady zielarskie "herbapol" s.a. - hippocastani seminis extractum + troxerutinum - Żel - (118 mg + 20 mg)/g

Imbruvica Європейський Союз - польська - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Calquence Європейський Союз - польська - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - białaczka, limfocytowa, przewlekła, komórka b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Brukinsa Європейський Союз - польська - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Środki przeciwnowotworowe - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Jaypirca Європейський Союз - польська - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - chłoniak, mantle-cell - inhibitory białka kinazy - treatment of mantle cell lymphoma (mcl).